1-3 of 3
Joseph T. Hadala
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

Tracy T. Chow, Nicholas Stong, Saleh Tamim, Chad C. Bjorklund, Antonina Kurtova, Keyur Desai, Joseph T. Hadala, Cynthia Donahue, Phillip Koo, Yue Zhu, Jessica Katz, Anita K. Gandhi, Suzanne Trudel, Nizar J. Bahlis, Paul G. Richardson, Michael Amatangelo
Journal: Blood
Blood (2024) 144 (Supplement 1): 3261.
https://doi.org/10.1182/blood-2024-199019
Published: 2024
Journal Articles

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Facon, Cesar Rodriguez, Ralph Wäsch, Meletios A. Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab
Journal: Blood
Blood (2024) 144 (Supplement 1): 1025.
https://doi.org/10.1182/blood-2024-198408
Published: 2024
Journal Articles

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Noopur Raje, Robert Vescio, MD, Charles W. Montgomery, MD, Joseph T Hadala, MS, Ghulam Warsi, PhD, Solveig G. Ericson, MD, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2012) 120 (21): 4077.
https://doi.org/10.1182/blood.V120.21.4077.4077
Published: 2012